Ghosh Sanchita, Liang Yutong, Cai Weibo, Chakravarty Rubel
Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai, 400085, India.
Homi Bhabha National Institute, Anushaktinagar, Mumbai, 400094, India.
J Nanobiotechnology. 2025 Jun 2;23(1):407. doi: 10.1186/s12951-025-03472-1.
In situ radiochemical doping presents a transformative approach for synthesizing radiolabeled inorganic nanoparticles (NPs) for cancer theranostics. Traditional radiolabeling techniques rely on bifunctional chelators, which often require harsh reaction conditions that can degrade the physicochemical properties of NPs. Additionally, the enzymatic dissociation of radiometals can potentially induce in vivo toxicity. In contrast, in situ doping directly incorporates radiometals into the NP crystal lattice, significantly enhancing both radiolabeling yield and radiochemical stability. This method preserves the pharmacokinetic profiles of the radiolabeled NPs, improving their theranostic efficacy. This review provides an up-to-date overview of the progress made in the development of radiolabeled inorganic nanoplatforms through in situ doping, with a focus on their stability, physicochemical characteristics, and applications in cancer theranostics. Our findings highlight the advantages in situ doping as a more efficient and stable alternative to conventional radiolabeling methods, offering substantial potential for the development of more effective cancer theranostic agents.
原位放射化学掺杂为合成用于癌症诊疗的放射性标记无机纳米颗粒（NPs）提供了一种变革性方法。传统的放射性标记技术依赖于双功能螯合剂，这通常需要苛刻的反应条件，可能会降低纳米颗粒的物理化学性质。此外，放射性金属的酶解可能会潜在地诱导体内毒性。相比之下，原位掺杂直接将放射性金属掺入纳米颗粒晶格中，显著提高了放射性标记产率和放射化学稳定性。这种方法保留了放射性标记纳米颗粒的药代动力学特征，提高了它们的诊疗效果。本综述提供了通过原位掺杂开发放射性标记无机纳米平台所取得进展的最新概述，重点关注其稳定性、物理化学特性以及在癌症诊疗中的应用。我们的研究结果突出了原位掺杂作为传统放射性标记方法更高效、稳定的替代方法的优势，为开发更有效的癌症诊疗剂提供了巨大潜力。
